Cleared Traditional

K874727 - PRECEPT(TM) CIPROFLOXACIN

K874727 is an FDA 510(k) clearance for PRECEPT(TM) CIPROFLOXACIN, manufactured by Austin Biological Laboratories. The device is a Class 2 Microbiology device with product code JWY cleared through the Traditional 510(k) pathway after a 92-day FDA review.

K874727 · Austin Biological Laboratories · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 1988
Decision
92d
Days
Class 2
Risk

K874727 is an FDA 510(k) clearance for the PRECEPT(TM) CIPROFLOXACIN. Classified as Manual Antimicrobial Susceptibility Test Systems (product code JWY), Class II - Special Controls.

Submitted by Austin Biological Laboratories (Austin, US). The FDA issued a Cleared decision on February 18, 1988 after a review of 92 days - within the typical 510(k) review window.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.1640 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Microbiology review framework, consistent with the majority of Class II 510(k) submissions.

View all Austin Biological Laboratories devices

FDA 510(k) Submission Details - K874727

510(k) Number K874727 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 18, 1987
Decision Date February 18, 1988
Days to Decision 92 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
10d faster than avg
Panel avg: 102d · This submission: 92d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

JWY Device Classification - Class 2, Special Controls

Product Code JWY Manual Antimicrobial Susceptibility Test Systems
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.1640
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - JWY Manual Antimicrobial Susceptibility Test Systems

All 406
Devices cleared under the same product code (JWY) and FDA review panel - the closest regulatory comparables to K874727.
GRAM NEGATIVE MIC/COMBO PANELS
K880430 · Baxter Healthcare Corp · Apr 1988
MODIFICATIONS TO API UNISCEPT (R) KB
K880598 · Analytical Products, Inc. · Mar 1988
ADDITION OF AMPICILLIN/SULBACTAM & CIPROFLOXACIN
K880617 · Pasco Laboratories, Inc. · Mar 1988
GRAM - & GRAM + MIC/COMBO & BREAKPOINT/COMBO PANEL
K874876 · Baxter Healthcare Corp · Jan 1988
API UNISCEPT(R) MICRO-MIC(R) SYSTEM/UNISCEPT MIC
K874466 · Analytical Products, Inc. · Dec 1987
NEW ANTIMICRO. AGENTS:AUGMENTIN,AZTREONAM,CIPROFLO
K874426 · Bd Becton Dickinson Vacutainer Systems Preanalytic · Dec 1987